CVGD - ETF AI Analysis
Top Page
CresAlta Global Dividend ETF (CVGD)
CVGD, the CresAlta Global Dividend ETF, earns a solid overall rating driven mainly by strong, cash-generative holdings like Verizon, Microsoft, Salesforce, and Gilead, which combine attractive valuations, positive earnings sentiment, and growth in areas such as cloud, AI, and key drug portfolios. However, weaker names like CVS and Diageo, which face profitability challenges, leverage concerns, and bearish technical trends, modestly weigh on the fund’s appeal, and investors should note the risk that several core holdings operate in mature, highly competitive sectors where overvaluation or margin pressure could hurt future returns.
CVGD vs. SPDR S&P 500 ETF (SPY)
- AUM
- 140.75M
- Region
- Global
- Expense Ratio
- 0.50%
- Beta
- 0.00
- Issuer
- CresAlta
- Inception Date
- May 18, 2026
- Dividend Yield
- 0.78%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
CVGD Summary
CresAlta Global Dividend ETF (CVGD) is an actively managed fund that focuses on companies around the world that pay steady, growing dividends, with most of its holdings in the U.S. It doesn’t track a fixed index, but follows a dividend-growth theme, choosing businesses with strong finances and solid cash flow. Well-known holdings include Microsoft and Verizon, along with health care, financial, and consumer companies. Investors might consider CVGD for diversified stock exposure plus potential income from dividends. A key risk is that stock prices and dividend payments can still go up and down with the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because CVGD is actively managed, with professionals selecting and monitoring dividend-focused stocks around the world.
What would affect this ETF?
This global dividend ETF could benefit if healthcare, financial, and defensive consumer companies remain stable and grow their profits, supporting steady or rising dividends across U.S. and international markets, especially from major holdings like CVS Health, Verizon, and Elevance Health. On the other hand, higher interest rates, economic slowdowns, or regulatory changes in healthcare and financials could pressure company earnings and dividend growth, while its active management approach may underperform if stock selection or sector bets do not work as expected.
CVGD Top 10 Holdings
CVGD leans heavily on steady dividend payers in health care and telecom, with names like Gilead and Elevance Health helping anchor returns as their long-term stories remain intact despite some recent bumps. Verizon and Japan’s KDDI add a global telecom flavor, with mixed but generally rising momentum that supports the fund’s income theme. On the weaker side, CVS and Huntington Bancshares have been lagging, acting as a bit of a brake. Microsoft provides a touch of Big Tech growth, but the fund’s core engine is global, defensive, dividend-focused stalwarts.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ELV | Elevance Health | 3.95% | $5.60M | $90.76B | 30.48% | 76Outperform |
 CRM | Salesforce | 3.60% | $5.11M | $188.61B | -10.71% | 80Outperform |
 CVS | CVS Health | 3.56% | $5.04M | $115.43B | 17.68% | 64Neutral |
 VZ | Verizon | 3.63% | $5.14M | $185.39B | 14.81% | 81Outperform |
 IMBBY | Imperial Brands | 3.07% | $4.35M | $29.45B | -1.27% | 74Outperform |
 HBAN | Huntington Bancshares | 3.00% | $4.24M | $31.80B | 3.00% | 80Outperform |
 SJM | JM Smucker | 2.99% | $4.24M | $13.88B | 26.92% | 49Neutral |
 MRSH | Marsh & McLennan Companies | 2.79% | $3.95M | $95.40B | 12.29% | 71Outperform |
 DEO | Diageo | 2.80% | $3.96M | $52.39B | 2.68% | 60Neutral |
CVGD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CVGD, the sentiment is Positive. The current price of 26.80 is above the 20-day moving average (MA) of 26.08, above the 50-day MA of 26.18, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 64.92 is Neutral, neither overbought nor oversold. The STOCH value of 67.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVGD.
CVGD Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| CVGD | $26.80 | $27.00(0.75% Upside) | $140.75M | 0.50% | 62Neutral |
 RGEF | $33.91 | $44.49(31.20% Upside) | $798.12M | 0.55% | 71Outperform |
 KAT | $59.06 | $67.45(14.20% Upside) | $668.77M | 0.75% | 64Neutral |
 DWLD | $44.30 | $58.72(32.54% Upside) | $567.47M | 0.62% | 62Neutral |
 RGLO | $32.67 | $41.10(25.79% Upside) | $370.72M | 0.49% | 68Neutral |
 JSTC | $23.38 | $28.01(19.78% Upside) | $300.92M | 0.89% | 60Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CVGD | CresAlta Global Dividend ETF | 26.80 | 1.83 | 7.35% | |
| RGEF | Rockefeller Global Equity ETF | 33.91 | 3.87 | 12.89% | |
| KAT | Scharf ETF | 59.06 | 5.36 | 9.98% | |
| DWLD | Davis Select Worldwide Etf | 44.30 | -0.54 | -1.19% | |
| RGLO | Global Equity Active ETF | 32.67 | 3.73 | 12.88% | |
| JSTC | Adasina Social Justice All Cap Global ETF | 23.38 | 3.33 | 16.63% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.